POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions for maintenance of electrolyte balance; dextrose provides caloric support; sodium chloride maintains extracellular fluid osmolarity.
| Metabolism | Potassium and sodium are not metabolized; dextrose is metabolized via glycolysis and oxidative phosphorylation. |
| Excretion | Primarily renal (90% as potassium ions), with minor fecal (10%) and negligible biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours for potassium ions, reflecting rapid renal clearance but can be prolonged in renal impairment. |
| Protein binding | Minimal; potassium ions do not bind significantly to plasma proteins (<1%). |
| Volume of Distribution | Total body water distribution, approximately 0.5-0.6 L/kg, reflecting intracellular (98%) and extracellular (2%) compartments. |
| Bioavailability | Oral: 90-100% (immediate-release formulations); intravenous: 100% (direct bioavailability). |
| Onset of Action | Intravenous: immediate (within seconds to minutes) upon administration; oral: 30-60 minutes after absorption. |
| Duration of Action | Intravenous: 2-4 hours for electrolyte correction; oral: 4-6 hours for sustained potassium repletion. |
Intravenous infusion; rate and volume determined by electrolyte needs and fluid status; typical maintenance: 0.9% sodium chloride with 20 mEq/L potassium chloride at 125 mL/hour; potassium chloride 0.3% provides 40 mEq/L, dextrose 5% and sodium chloride 0.11% provides 19 mEq/L sodium; consult institutional protocols.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment; GFR 30-50 mL/min: reduce potassium infusion rate by 50% and monitor serum potassium; GFR <30 mL/min: avoid potassium administration unless severe deficiency with close monitoring; use with caution in oliguria. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: monitor potassium levels closely; Child-Pugh C: use with caution, reduce infusion rate by 25-50% and monitor for hyperkalemia. |
| Pediatric use | Weight-based: 0.5-1 mEq/kg/day of potassium, maximum infusion rate 0.5-1 mEq/kg/hour; administer as continuous infusion; typical solution: 20-40 mEq/L potassium in compatible IV fluid; adjust based on serum potassium and clinical status. |
| Geriatric use | Reduce initial infusion rate by 25-50% due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion; consider lower potassium concentration (20 mEq/L) initially. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and sodium are normal milk constituents; dextrose infusion does not alter milk composition significantly. No adverse effects expected. M/P ratio not applicable as these are endogenous substances. |
| Teratogenic Risk | No known teratogenic risk; potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No specific trimester risks identified at standard doses. However, maternal hyperkalemia or hypoglycemia may indirectly affect fetal outcome. |
■ FDA Black Box Warning
No FDA black box warning for this combination product.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Renal failure with oliguria or anuria","Addison's disease","Acute dehydration","Heat cramps","Patients receiving potassium-sparing diuretics"]
| Precautions | ["Monitor serum potassium to avoid hyperkalemia","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Check for signs of fluid overload or electrolyte disturbances","Do not administer concentrated potassium solutions; must be diluted"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, glucose), fluid balance, and renal function. Fetal heart rate monitoring if clinically indicated (e.g., for maternal metabolic disturbances). |
| Fertility Effects | No known effects on fertility; these are physiological components and do not alter reproductive function. |